期刊文献+

从“脾肾”论治结直肠癌化疗毒副反应28例临床观察 被引量:3

原文传递
导出
摘要 目的:研究健脾益肾中药配合mFOLFOX6方案化疗是否能减轻结直肠癌患者化疗毒副反应;方法 :共有56例II期-IV期患者被随机分为两组。治疗组28例,mFOLFOX6化疗同时每天服用健脾益肾中药(我科室自制中药制剂—扶正升白口服液)。对照组28例,常规mFOLFOX6方案化疗。观察两组化疗前后骨髓抑制、胃肠道反应、肝功能、神经毒性等发生率的差别。结果 :治疗组WBC和PLT下降发生率均低于对照组(P<0.05)。但两组HGB下降发生率无统计学差异(P>0.05)。2、胃肠道反应、肝功能、神经毒性等方面两组发生率无差异(P>0.05)。结论:扶正升白口服液联合mFOLFOX6方案化疗能减轻结直肠癌患者骨髓抑制方面的毒副反应。
作者 汤秀红
机构地区 南京市中医院
出处 《黑龙江中医药》 2017年第2期18-19,共2页 Heilongjiang Journal of Traditional Chinese Medicine
  • 相关文献

参考文献7

二级参考文献70

  • 1Xu, An-Gao,Yu, Zhi-Jin,Jiang, Bo,Wang, Xin-Ying,Zhong, Xu-Hui,Liu, Ji-Hong,Lou, Qiu-Yun,Gan, Ai-Hua.Colorectal cancer in Guangdong Province of China:A demographic and anatomic survey[J].World Journal of Gastroenterology,2010,16(8):960-965. 被引量:40
  • 2Akram Yusup,Hai-Jiang Wang,Azmat Rahmutula,Parhat Sayim,Ze-Liang Zhao,Guo-Qing Zhang.Clinical features and prognosis in colorectal cancer patients with different ethnicities in Northwest China[J].World Journal of Gastroenterology,2013,19(41):7183-7188. 被引量:15
  • 3刘宁,种道群,袁蕾蕾,国桂松,黄建国.国产奥沙利铂联合亚叶酸钙和5-氟脲嘧啶治疗晚期结直肠癌的临床观察[J].临床肿瘤学杂志,2004,9(5):484-485. 被引量:6
  • 4朱青山,陈雅敏,刘基巍,于佩瑶.奥沙利铂联合5-氟尿嘧啶、亚叶酸钙治疗晚期消化道肿瘤的临床观察[J].肿瘤防治研究,2006,33(4):268-269. 被引量:10
  • 5Koopman M, Antonini NF, Douma J, et al. Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO) : a phase Ⅲ randomised controlled trial [J]. Lancet, 2007, 370 ( 9582 ) : 135-142.
  • 6Seymour MT, Maughan TS, Ledermann JA,et al. Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer ( MRC FOCUS) : a randomised controlled trial [J]. Lancet, 2007,370 (9582) : 143-152.
  • 7Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer[J]. N Engl J Med,2004, 350(23) :2335-2342.
  • 8Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and ce-tuximab plus irinotecan in irinotecan refractory metastatic colorectal cancer[J]. N Engl J Med, 2004,351 (4) :337-345.
  • 9Tol J, Koopman M, Rodenburg C J, et al. A randomised phase III study on capecitabine, oxaliplatin and bevacizumab with or without cetuximab in first-line advanced colo-rectal cancer, the CAI-RO2 study of the Dutch Colorectal Cancer Group (DCCG) : an interim analysis of toxicity [J]. Ann 0ncol,2008,19 (4) :734-738.
  • 10Moroni M,Veronese S, Benvenuti S, et al. Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: A cohort study[J]. Lancet Onco1,2005,6(5 ) :279-286.

共引文献119

同被引文献39

引证文献3

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部